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Objectives. The aim of this study was to assess the incidence, the prenatal detection rate by ultrasound, and the pregnancy outcome
of spina bifida (SB) in Denmark (DK) in 2008–2015 and to compare results to national data from Sweden. Methods. Data were
retrieved from the Danish Fetal Medicine Database, which includes International Classification of Diseases- (ICD-) 10 codes for
pre- or postnatally diagnoses and pregnancy outcome.Missing datawere obtained from theNational Patient Register. Livebirth data
with myelomeningocele (MMC) in Sweden were obtained from different databases. Results. There were 234 cases with SB in DK in
2008–2015.The incidence of SBwas 4.9 : 10,000; 89%were detected with ultrasound prior to week 22; 90% of these pregnancies were
terminated (ToP); 91% were isolated malformations of which 11% showed abnormal karyotype. The incidence of newborns with
MMC was 1.3 : 10,000 in Sweden. Conclusions. Ultrasound screening has a major impact on the epidemiology of SB. The prenatal
detection rate of SB was high, and most SB cases were isolated and had a normal karyotype. Among women with a prenatal fetal
diagnosis of SB, 90% chose to have ToP. The incidence of newborns with SB was higher in Sweden than in DK.
1. Introduction
Since the introduction of new guidelines for prenatal diag-
nostics in 2004, all pregnant women in Denmark have been
offered a prenatal screening program.Theprogramcomprises
two ultrasound scans during their pregnancy: one in ges-
tational weeks 11–14 (scanning primarily for chromosomal
abnormalities) and one in gestational weeks 18–21 (scanning
primarily formalformations) as well asmidwife consultations
between the scans [1]. These guidelines were issued by the
Danish Health Authority in 2004. They were not designed
to eradicate disease but to support pregnant women’s repro-
ductive autonomy, confirm normality by offering ultrasound
and possibly genetic testing, facilitate planning of optimal
postnatal care, and give women the possibility of applying
for late termination of pregnancy (ToP) in case of severe fetal
disease, like spina bifida (SB), within week 22 + 0.The current
screening uptake is approximately 97%.
SB is a birth defect in the group of neural tube defects
(NTD). It results from failed closure of the neural folds during
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the first month of gestation. SB is associated with severe
morbidity and mortality, depending on the type, size, and
site of the lesion [2, 3]. The incidence of SB differs globally
from 1.7 to 19 : 10,000 fetuses [4–12]. SB can be detected
in the second trimester using ultrasound which will reveal
specific cranial signs of the cerebellum and the skull [13].
Previous studies have shown that intake of folic acid during
pregnancy may decrease the risk of SB [6, 7]. This has made
some countries use mandatory food fortification to ensure
adequate supply of folic acid to pregnant women [6, 14]. In
Denmark, folic acid is recommended as a food supplement
from the day pregnancy is planned, but it is not added to food
as part of a mandatory scheme. Danish folic acid recom-
mendations have shown no impact on the incidence of SB
fetuses inwestern parts of the country due toDanish pregnant
women not complying with the guidelines and thus not
getting the recommended amount of folic acid [15–17]. Even
so, one of these studies showed a decrease in the incidence
of infants born with SB after year 2006, that is, at the same
time as the above-mentioned prenatal screening programwas
introduced at all obstetric departments inDenmark [16].This
suggests that the use of ultrasound scans may have an impact
on the epidemiology of SB in Denmark.
Different countries have developed various prenatal ultra-
sound strategies to manage pregnancies complicated by SB.
In Sweden, another Scandinavian country with a population
approximately twice the size of the Danish population and
similar legislation regarding ToP, second-trimester ultra-
sound scan is also offered to all pregnant women. In Sweden,
however, the proportion of women who accept prenatal
ultrasound screening varies more across regions than in
Denmark.
The objectives of this study were to estimate the true
incidence of SB in Denmark, to assess the detection rate
at first-trimester and second-trimester ultrasound screening,
to identify pregnancy outcomes in years 2008–2015, and to
identify similarities as well as differences in incidence of SB
between Denmark and Sweden.
Overlapping and sometimes inconsistent terms are used
for spinal NTDs [18]. In the present study, the term “spina
bifida” includes all open spinal NTDs and meningocele and
lipomatous malformations with neurological deficits of the
skin-covered SB.
2. Method
2.1. 	e Danish Fetal Medicine Database. Data for this study
were primarily obtained from the Danish Fetal Medicine
Database (DFMD), which is a national database that includes
data from all obstetric departments in Denmark.The DFMD
contains information on all pregnancies in DK with a first-
trimester scan from 1 January 2008. With an uptake of more
than 90%, this corresponds to 50, -60,000 pregnancies per
year. The DFMD receives information regarding maternal
and pregnancy characteristics and International Classifica-
tion ofDiseases- (ICD-) 10 codes for any prenatally diagnosed
anomaly automatically from the prenatal software system
(Astraia GMBH, Munich, Germany) used in all obstetric
Danish Birth Registry 2008–
2015:
n = 475,679 pregnancies
(100%)
(i) DuplicateＭ = 6
(ii) No SB historＳ = 108
(iii) Occulta, tethered cor＞ = 23
(iv) OtheＬ = 4
Excluded: 141
n = 443,617 (93.3%)
Danish Fetal Medicine
Database:
n = 32.062
No prenatal scan
n = 370
ICD-10 code DQ050–
DQ059:
n = 229
True spina biﬁda cases:
Figure 1: Flowchart of inclusion from the Danish Fetal Medicine
Database (DFMD).
departments. Data are linked with pre- and postnatal out-
comes from the Danish Cytogenetic Register, the National
Patient Register (NPR), and the National Birth Register. The
DFMD thus makes it possible to analyze >90% of the entire
population of pregnant women with regard to screening
results and outcomes [19].
2.2. Data Collection. Data were collected prospectively and
analyzed retrospectively. Firstly, we collected data from all
pregnancies in Denmark with due date in the period from 1
January 2008 to 31 December 2015 that underwent a second-
trimester ultrasound scan and had a pre- or postnatally
registered International Classification of Disease- (ICD-) 10
code in the range of Q050–Q059. We performed a search of
the Astraia software for cases that had ultrasound indications
of SB but lacked an ICD 10-code in the searched range to
identify cases that had been given an ICD 10-code not
included in our search, for instance, diagnoses in the Q06
group (“other congenital malformations of the spinal cord”).
Figure 1 provides an overview of the inclusion parameters.
We retrieved data regarding due date, prenatally diagnosed
anomaly, anomaly diagnosed at any time postnatally until
data extraction, coexistence of other malformations, kary-
otype, and outcome (live-born, ToP, and adverse pregnancy
outcome). No information on size and site of the lesion was
obtained.
Secondly, we collected all cases born in the study period
with an ICD-10 code for SB from the NPR and included Civil
Registration Numbers (CPR, which all citizens in Denmark
are given at birth or upon immigration) not already known
from the DFMD. In this way, we included SB cases among
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From the NPR: patients born
between 2008–2015 with
n = 199
Q05-code registered:
n = 98
Already known
from DFMD
n = 101
New patients
n = 77
No relevant hospital
contact
n = 24
Seen in either a neurosurgical or a
pediatric surgical department
n = 12
Veriﬁed spina biﬁda cases
n = 5
Included:
Born and operated
in Denmark:
n = 7
Excluded: 
Born and operated
outside Denmark:
Figure 2: Flowchart of inclusion from the National Patient Register
(NPR), DFMD: Danish Fetal Medicine Database.
babies to the 7% of mothers who had not been scanned pre-
natally and therefore had not been registered in the DFMD.
We also evaluated patient files for cases with a neurosurgical
or pediatric surgical contact, seen in a hospital within the first
year of life. See the flowchart in Figure 2.
Medical records on all infants and mothers in whom a
ToP was performed (including autopsy results) were evalu-
ated for validation. This made it possible to collect missing
data, and cases were included or excluded according to the
European Surveillance of Congenital Malformation (EURO-
CAT) guidelines [20].This meant that we excluded all infants
with SB occulta, lipomatous malformations, or tethered cord
without neurological deficits, as well as all suspected but not
confirmed SB cases. Babies born and having had primary
surgery outside of Denmark were excluded from further
statistical analysis (𝑛 = 7). Fetal closure of open SB had not
been performed on any of these fetuses.
2.3. Statistical Analysis. Data were stored using RedCap soft-
ware and exported to STATA 14 for analysis. Student’s 𝑡-test
and Wilcoxon–Mann–Whitney test were used for numerical
data, and chi2 -test was used for binominal data. Variation
over years was tested by a Poisson regression model, and
ToP rates and detection rates were analyzed using binomial
probability tests.
𝑝 < 0.05was considered statistically significant; 95% con-
fidence intervals are presented after each result in brackets.
2.4. Sweden. Data from Sweden were collected from the
national follow-up program and quality of care registry in
spinal dysraphism and hydrocephalus. The SB part of the
follow-up program, called the MMCUP, includes a lifelong
follow-up of body function/structures, activity, participation,
treatment, and self-reported health-related quality of life for
all children with SB born between 2007 and 2015 in Sweden
[21]. The MMCUP provides information on live born but
not unborn fetuses like the Danish registers. Hence, from
Sweden, fetuses terminated by ToP or still births were not
included. We extracted data from the MMCUP on SB and
the prenatal diagnosis for all infants born in Sweden from 1
January 2008 to 31 December 2015.
Data on the total number of births in Sweden were
obtained from the Swedish population registry, Statistics Swe-
den. We received extracted anonymized statistics on infants
and abortions coded with Q05 from the Swedish National
Board of Health and Welfare and the number of pregnancies
for the years 2008–2014 from the following registers: theMed-
ical Birth Register, the Swedish NPR, and the Surveillance
Register of Birth Defects. Only patients diagnosed prenatally
or within their first year of life were included. Numbers from
2015 were not available at the point of collection. Because of
differences in legislation on patient anonymity between the
two counties’ databases, it was not possible to validate any of
the Swedish cases.
2.5. Permissions. Permission to collect and store data was
obtained from the Danish Data Protection Agency (reference
number: 2012-58-006). Permission to look at the patient files
of the babies ofmothers who had not been scanned prenatally
was granted by theDanish Patient Safety Authority (reference
number: 3-3013-1721/1). Ethical approval for the MMCUP
was provided in Lund, Sweden (EPN Lund, 241-2009).
3. Results
3.1. Incidence. There were 475,679 pregnancies in Denmark
from 2008 to 2015. A total of 234 true SB cases were included
in the study population (Figure 1). The incidence of pregnan-
cies complicated by SB was 4.9 : 10,000 [4.3–5.6 : 10,000], and
this incidence did not differ over the years 2009–2015 (𝑝 =
0.81), except in 2008 when there was a significantly lower
incidence of pregnancies with SB (𝑝 = 0.03). The incidence
of live-born SB cases was 0.8 : 10.000 [0.6–1.1 : 10,000] with no
significant difference between the years (𝑝 = 0.7).
There were 7 additional cases born and treated outside
Denmark but followed in a Danish hospital after immigra-
tion.
3.2. Prenatal Diagnosis. Of the 234 cases, 223 had an ultra-
sound scan done before 22 weeks, whereas 6 did not attend
screening until later in pregnancy, and no information on
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Table 1: Spina bifida cases and detection divided in years; ∗Poisson regression.
Year Total SB cases Prenatal diagnosis Prenatal diagnosis < week 22
2008 15 14 (93.3%) 13 (86.7%)
2009 32 29 (90.6%) 27 (84.4%)
2010 38 35 (92.1%) 34 (89.4%)
2011 33 30 (90.9%) 28 (84.8%)
2012 28 27 (96.4%) 26 (92.9%)
2013 24 21 (87.5%) 21 (87.5%)
2014 35 34 (97.1%) 31 (88.6%)
2015 29 29 (100%) 27 (93.1%)
Total 234 219 (93.6%) 207 (88.5%)
𝑝 value 0.99∗ 0.99∗
Table 2: Maternal characteristics from the Danish Fetal Medicine Database; ∗Wilcoxon–Mann–Whitney test, ∗∗Student’s 𝑡-test, ∗∗∗chi2 test;
∧Caucasian: European, Middle Eastern, North African, Hispanic; ∧∧Non-Caucasian: Afro Caribbean, Asian, Oriental.
Characteristic <week 22 ≥week 22 𝑝 value
𝑁 = 187 𝑁 = 16
Maternal age, years [95% CI] 29.7 [29.0; 30.4] 29.8 [27.4; 32.1] 0.88∗
BMI, [95% CI] 25.6 [24.7; 26.5] 28.1 [24.9; 31.3] 0.08∗∗
Smokers, % [95% CI] 3.8 [1.5; 7.6] 6.2 [0.2; 30.2] 0.62∗∗∗
Ethnicity, % [95% CI]
(i) Caucasian∧ 93.2 [88.6; 96.3] 86.7 [59.5; 98.3] 0.35∗∗∗
(ii) Non-Caucasian∧∧ 6.8 [3.7; 11.4] 13.3 [1.7; 40.5]
Conception, % [95% CI]
(i) Spontaneous 90.1 [84.8; 94.0] 93.8 [69.8; 99.8] 0.63∗∗∗
(ii) Fertility treatment 9.9 [6.0; 15.2] 6.3 [0.2; 30.2]
screening was available in 5 cases. Prenatal detection at any
gestational age was achieved in 93.6% [89.6–96.4%] (219/234)
of cases, and 88.5% [83.7–92.5%] had been detected prior to
week 22 (207/234) (stratified by years in Table 1).
We divided data onmaternal characteristics fromDFMD
into two subgroups according to gestational age at diagnosis
to rule out baseline characteristics as reason for nondetection
(Table 2). Complete baseline data were available for 187 out of
207 (<week 22) and for 16 out of 22 (≥week 22), respectively.
There was no significant difference between the two groups
of mothers regarding age, body mass index (BMI), ethnicity,
smoking status, or mode of conception. No information was
obtained regarding mothers of the 5 babies with SB who had
not been scanned prenatally.
The sensitivity of the Danish screening program was
92.8% [88.6–95.8%], since 207 of the 223 who attended
screening were diagnosed before gestational week 22,
with 15.5% [10.8–21.1%] in the first (32/207) and 84.5%
(78.8–89.2%) in the second trimester (175/207).There was no
statistical variation in the prenatal detection rate during the
study period (𝑝 = 0.99).
Information about the type of SB was obtained for 14 of
the 16 cases not identified at screening; in 11 of these cases
(78.6%), the SB was skin-covered, meaning either meningo-
cele or lipomatous malformations, suggesting that close to all
of the opened SB cases were detected.
3.3. Outcome. In cases with a SB diagnosis made by ultra-
sound prior to week 22 of gestation, 90.3% [86.0–94.5%]
(187/207) of the women opted for termination. Of all
234 cases, 190 resulted in ToP, corresponding to 81.6%
[76.1–86.4%] of all SB cases in Denmark.The tendency to opt
for termination did not change significantly within the study
period (𝑝 = 0.99).
In the database, ethnicity is coded as “Caucasian” (Euro-
pean, Middle Eastern, North African, and Hispanic), Afro
Caribbean, Asian, and Oriental. However, as there were very
few numbers in the last three groups, we assembled them
together in one group, calling it “Non-Caucasian.” Among
mothers of Non-Caucasian origin, 30.7% chose to continue
their pregnancy when SB was diagnosed before week 22.
This was higher than the 6.3% in the Caucasian group (𝑝 =
0.0015). No difference was noted between the two groups
regarding mode of conception (𝑝 = 0.13) or maternal age
(𝑝 = 0.08).
A total of 20 women chose to continue their pregnancy
with a SB diagnosis by ultrasound before 22 weeks. 16 of
these women had a live-born baby and four miscarried. Of
the 27 cases without a prenatal diagnosis before week 22, 22
had a live-born baby, one miscarried, and four opted for
termination, and since the fetuses were considered not viable
beyond 30 days, ToP was allowed in accordance with Danish
legislation.
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Table 3: Overview of differences between Sweden and Denmark 2008–2015; ∗2008–2014; ∗∗majority in third trimester; 𝑝 value calculated
by Student’s 𝑡-test.
Denmark Sweden 𝑝 value
Incidence fetuses 4.92 : 10,000 3.4 : 10,000∗ 0.0001
Incidence live births 0.8 : 10,000 1.3 : 10,000 0.04
ToP rate 81.2% 63.0%∗ 0.02
Prenatal detection RATE among live births 42.1% 56.3%∗∗ 0.11
The resulting overall number of live births with SB was
38. Of these, 14 had a skin-covered SB. This is on average 4-5
infants with any kind of SB per year and of these 3 had open
SB per year.
Of the 38 infants, 42.1% [25.7–58.6%] (16/38) had a
prenatal diagnosis <week 22: that is, 57.9% did not know they
were having a baby with SB.
In 91.3% [86.9–94.6%] of cases, SB was an isolated mal-
formation (hydrocephalus and club feet are considered sec-
ondary to SB and are not counted as other malformations). A
total of 119 (56.9%) of isolated cases had karyotypic or
chromosomal information available, and 10.9% [5.9–18.0%]
(13/119) were abnormal.
3.4. Results from Sweden. All live-born children with SB in
Sweden from 2008 to 2015, in total 121 children, were known.
Of these, 72% had an open and 28% had a skin-covered SB. A
total of 905,060 babies were born in Sweden during the same
period. Hence, the incidence of live-born infants with SB was
1.3 : 10,000 [1.1–1.6 : 10,000], which was higher (𝑝 = 0.04)
than in Denmark. Information on prenatal diagnosis was
available for 79% of these infants (96/121) and showed that
56.3% [46.1–66.4%] of the 96 infants had a prenatal diagnosis
of SB: that, 43.7% of the mothers had no knowledge that they
were expecting a baby with SB. This rate did not change over
the years (𝑝 = 0.88).
In the databases from the National Board of Health and
Welfare, which include data from 2008–2014, there were 308
unverified cases coded with SB (Q05) of whom 165 were
registered as ToP. According to the MMCUP, only 97 infants
born during 2008–2014 fulfilled the criteria for SB, as defined
above, compared with 143 infants with a Q05 diagnosis in the
national healthcare databases. Provided that all 165 ToP
fetuses had SB and that all live-born children with verified SB
were known (𝑛 = 97), the incidence of pregnancies with SB
was 3.4 : 10,000 [3.0–3.8 : 10,000] during 2008–2014, and the
ToP rate in Sweden based on verified SB was 63% [51.5–76.8]
(165/262).
Table 3 provides an overview of the differences in results
between Sweden and Denmark.
4. Discussion
This study is the first to cover the impact of prenatal
ultrasound screening on the incidence of SB on a national
level. In the Danish cohort, we found an incidence of SB of
4.9 : 10,000. The prenatal detection rate before 22 weeks was
high and themajority of these women opted for ToP resulting
in very few live births with SB. The rate of live births with
SB was higher in Sweden than in Denmark, probably due to
fewer women choosing prenatal diagnostics and possibly also
a lower prenatal detection rate.
Ultrasound-detectable signs of open SB include “banana
sign” of the cerebellum and “lemon sign” of the frontal skull
[13]. Closed SB does not have the same impact on cranial
structure as open SB and hence lacks the same ultrasound-
detectable features [22]. Previous studies have shown that the
sensitivity and specificity of ultrasound for open SB are close
to 100% [23]. In the Danish study population, we found a
sensitivity of 92.8%, and as our data also include some closed
SB types, the sensitivity is expected to be lower than 100%.
In Denmark, 88.5% of the total population of SB was
diagnosed before gestational week 22 and 93.9% at any ges-
tational age. The EUROCAT society and other studies report
prenatal detection rates in the range 81–90% [4, 8, 9, 24, 25].
Our overall prenatal detection rate was significantly higher
than the percentage (89.3%) reported by the EUROCAT
(𝑝 = 0.03), suggesting that the Danish prenatal screening
program outperforms those of other European countries
that pursue different strategies for prenatal screening for
anomalies.The superior performance of the Danish program
may likely be attributed to high coverage and acceptability.
This is corroborated by a recentDutch study [24]which found
the same proportion of pregnant women accepting a second-
trimester scan, and where 88% of SB cases are diagnosed in
the second trimester.
Among all Danish SB cases, 81.6% resulted in ToP, and of
those diagnosed with ultrasound before gestational week 22,
90.3% opted for termination.The ToP rate following prenatal
diagnosis was in the same range as for Alsace in France
(97%) [4] and the region Emilia-Romagna in Italy (92.4%)
[8] (only open SB), but higher than rates reported by the
EUROCAT (66%) [26], Atlanta in the US (34%) [12], and the
northern parts of the Netherlands (78.6% when diagnosed in
the second trimester) [24].
TheDanish Spina Bifida Society (“Rygmarvsbrokforenin-
gen af 1988”) does not have an official statement regarding
ToP, which somehow underlines the liberal attitude towards
ToP in Denmark and even among patients and relatives
affected by SB. The different attitudes towards ToP evident
between different ethnic groups in the present study and geo-
graphicallymay partly explain the varying global incidence of
live-born SB cases.
Today, the possibility for prenatal genetic counseling is
widely used for known hereditary diseases, and the intro-
duction of prenatal ultrasound has made it possible to
offer genetic counseling to parents expecting a child with a
malformation, like SB, that has no known hereditary path.
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A chromosomal abnormality was found in 10.9% of isolated
SB, which is comparable to the rates reported in similar
studies [4, 8, 10]. This suggests that there is a high risk of
chromosomal anomalies in these pregnancies compared with
normal-appearing fetuses [27] and supports the idea that all
womenwith a pregnancy complicated by SB should be offered
chromosomal analysis and counseling from a multispecialist
team.
It is important to note that previous studies included
only open SB [8, 9, 24] or were inconsistent as to whether
they included both open and closed SB [10–12, 28]. In our
definition of SB, we included open SB and meningocele
and lipomatous NTDs with neurological deficits. We did
not include information on size and site of the lesion. Our
study includes close to 100% of the Danish SB cases which
minimizes selection bias and regional differences. The num-
ber of SB cases was lower in 2008 than in the other years,
possibly due to natural variance over years or missing data in
the establishment period in the beginning of 2008. All cases
included in the study were validated by clinical audit and
patient file review, which eliminates the risk of false-positive
cases. A search of the Astraia software for cases that had
ultrasound indications but lacked an ICD 10-code for SB was
undertaken for the prenatally diagnosed group in an attempt
to diminish the risk of underestimation due to noninclusion
of false-negative cases. SB cases that died in utero earlier than
the second trimester could not be included; thus, this could
possibly lead to a small degree of underestimation. For the
postnatally diagnosed group, there is a small risk that patients
were not given a correct ICD 10-code and hence not reported
to the NPR. However, since all SB patients in Denmark are
referred to a university hospital, the risk of nonreporting is
low. We base this argument on the observation that ICD-
10 codes in Denmark serve multiple purposes, including the
distribution of funding between healthcare institutions.
The Danish incidence of SB is in line with that of other
western developed countries without food fortification [4, 7,
8, 24], whereas studies from other parts of the world where
mandatory fortification of grain products exists show a lower
total incidence of SB (USA, Canada, and Australia) [6, 12].
Validation of cases that are given ICD-codes for SB (Q05)
is absolutely necessary to identify the “true” incidence of
SB, as shown in Figures 1 and 2 for the Danish fetal and
patient registries. As infants and abortions coded with Q05
were anonymized in the Swedish National Board of Health
and Welfare data, validation of these cases could not
be undertaken. However, comparison with MMCUP data
regarding infants born with SB indicated that 32.2% of the
Swedish Q05-coded infants did not have SB, a proportion
that is about the same as that in Denmark according to
the present study. About two-thirds of the infants with SB
had an open, not skin-covered, defect in both countries.
The comparison between Denmark and Sweden under-
lines the difference between using an anonymized and a
nonanonymized database. The data from Sweden originate
from the MMCUP, which was not anonymized and from the
national populations registers, which were anonymized.
Hence, 97/143 cases in the national population registers were
present in theMMCUP, suggesting that 46 (32.2%) were false
positive in the database. An even higher proportion of false-
positives were found in the Danish Patient Registers after full
validation of the nonanonymized data, with 108/229 (47.2%)
having a wrong diagnosis.
Sweden has the same folic acid recommendations as
Denmark [28], and the lower incidence of pregnancies with
SB in Sweden than in Denmark (3.4 versus 4.9 : 10,000, 𝑝 <
0.001, Table 3) must therefore be due to other factors. A
previous Swedish study found a national incidence of SB of
5.44 : 10,000 during 1999–2002 [28], which is significantly
higher than the estimated incidence based on the present 308
pregnancies with unverified SB. So, poor identification of
registered pregnancies may have contributed to the low
incidence figures for the years 2008–2014 in the present study.
Despite the possibly lower incidence of pregnancies with SB,
the higher incidence of infants born with SB in Sweden
than in Denmark may be explained by a lower percentage of
parents choosing prenatal diagnostics, lower detection by
ultrasound, and possibly different attitudes towards ToP.
To our knowledge, valid national prevalence figures on SB
cases with prenatal ultrasound findings did not exist prior to
this study, either in Denmark or in any other country. The
present study shows that a full national prenatal ultrasound
screening with a high uptake has a major impact on the inci-
dence of SB because of the high detection rate of SB by ultra-
sound and because a large proportion of women opt for ToP.
This study may have implications for the organization of
SB prenatal care, surgery, and treatment. Since the patient
volume is low with an average of only four new patients per
year, patients who need lifelong treatment may be better han-
dled in a few dedicated centers to optimize the expertise of
healthcare professionals and to ensure better quality of life for
patients.
5. Conclusion
This study includes all fetal SB cases in Denmark during the
years 2008–2015. The study shows that, by using ultrasound
screening, almost all cases of a SB can be detected. In a
country like Denmarkwhere ToP is regulated by law, prenatal
ultrasound screening may have an impact on the number of
live births of children with ultrasound-detectable malforma-
tions, and it may inform healthcare professional and parental
decisions with regard to ToP and the planning of postnatal
care for the newborn. The difference between Denmark and
Sweden, where acceptance of prenatal ultrasound screening
is lower, underlines the effect of a nationwide screening
program on the epidemiology of SB.
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fetal spina bifida cases were detected by prenatal ultrasound
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in case of open spina bifida, so very few infants with this
malformation were born.
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